RxDoctor Payments Data

Nicole Parsons

Adult Health · Jamaica, NYNPI 1174953269

Payments from drug & device makers

$3,209in general payments, 2019–2025

Across 119 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$420
  • Merck$140
  • Janssen Products, LP$125
  • Johnson & Johnson$106
  • Theratechnologies Inc.$102
  • plus $218 from 5 others

What the payments were for

  • Food & beverage$3,209100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,209 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$4,420
Medicare patients
20
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala106$408,520
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$88,266
GenvoyaElviteg/Cob/Emtri/Tenof Alafen21$83,396
DescovyEmtricitabine/Tenofov Alafenam29$61,148
DovatoDolutegravir Sodium/Lamivudine20$55,598
TriumeqAbacavir/Dolutegravir/Lamivudi14$47,156
TivicayDolutegravir Sodium12$25,445
PrezistaDarunavir11$23,295
IsentressRaltegravir Potassium11$21,610
EliquisApixaban11$6,431
Ritonavir11$4,580
Zafirlukast14$488
ValacyclovirValacyclovir Hcl16$354
Atorvastatin Calcium42$141
Famotidine14$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$420$553,064156 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay$2,098$128,19946 claims
MerckIsentress$140$21,61011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →